Pharmaceuticals group Elan said yesterday that the US Food and Drug Administration had approved its muscle spasm treatment, Myobloc, already cleared in the EU under the name NeuroBloc.

Neurobloc was cleared last month by the European Union's Committee for Proprietary Medicinal Products and is now being considered by the European Commission for marketing authorisation, a process which can take several months.